Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio- DARPin TherapeuticsCo-Development Agreement • October 22nd, 2024
Contract Type FiledOctober 22nd, 2024Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)